![[e-mail]](http://wwwcache.wral.com/presentation/v2/images/header/email-15x10.gif){kind=small}
Subscribe
![[e-mail]](http://wwwcache.wral.com/presentation/v1/images/icon_email-story.gif){kind=icon}
Get News Alerts to your Email & Cell Phone
RESEARCH TRIANGLE PARK, N.C. — Cato Research
and Cato BioVentures have struck a business development deal with VistaGen Therapeutics.
Under the contract, VistaGen, which is based in Burlingame CA, gets exclusive rights of first negotiation for all central nervous system (CNS) product opportunities that Cato and Cato BioVentures identify or acquire.
Financial terms were not disclosed.
Cato BioVentures is the venture capital arm of Cato, an RTP-based contract research organization.
"VistaGen's CNS focus and leading embryonic stem cell-based drug discovery and development technology provide an ideal leverage opportunity for our expanding CNS product acquisition and investment activities," said Shawn Singh, managing principal of Cato BioVentures who also is a member of VistaGen's board of directors. "VistaGen's management team is strong, its core technology is broadly applicable and its technical expertise is deep."
![[SLIDESHOW]](http://wwwcache.wral.com/asset/share/2012/02/09/10711513/4f348e7981bb5-51x75.jpg)
![[SLIDESHOW]](http://wwwcache.wral.com/asset/news/local/2012/02/11/10717396/thumbnail-100x75.jpg)
![[SLIDESHOW]](http://wwwcache.wral.com/asset/entertainment/out_and_about/2012/02/04/10712136/pics_agunn53833-100x75.jpg)
![[SLIDESHOW]](http://wwwcache.highschoolot.com/asset/content/2012/02/11/10717011/10717011-1328936455-100x75.jpg)
![[SLIDESHOW]](http://wwwcache.highschoolot.com/asset/content/2012/02/11/10717059/10717059-1328939591-100x75.jpg)
![[SLIDESHOW]](http://wwwcache.highschoolot.com/asset/content/2012/02/11/10717043/10717043-1328939633-100x75.jpg)
WRAL.com welcomes your comments on this story. All comments are moderated prior to publication based on our posting guidelines. Please review them prior to posting and if your message is not approved.
This story is closed for comments. Comments on WRAL.com news stories are accepted and moderated between the hours of 8 a.m. and 8 p.m. Monday through Friday.